Investigator
The University of Texas MD Anderson Cancer Center, Epidemiology
PPP2R1A mutations portend improved survival after cancer immunotherapy
Immune checkpoint blockade (ICB) therapy is effective against many cancers, although resistance remains a major issue and new strategies are needed to improve clinical outcomes
Researcher
The University of Texas MD Anderson Cancer Center · Epidemiology
Duke University
